Global Age Related Macular Degeneration Amd Disease Anti Vegf Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2022 –2029 |
 Tamanho do mercado (ano base ) | USD 13,677.02 Million |
 Tamanho do mercado ( Ano de previsão) | USD 22,951.90 Million |
 CAGR |
% |
| Principais participantes do mercado |
|
>Doença global de degeneração macular relacionada com a idade (DMI) – Mercado Anti VEGF, por tipo (DMI seca e DMRI húmida), utilizador final (hospitais, clínicas especializadas, centros de cirurgia ambulatória , assistência médica domiciliária, entre outros), canal de distribuição ( concurso direto e Vendas a retalho) - Tendências e previsões do setor para 2031.
Doença de Degeneração Macular Relacionada com a Idade (DMI) – Análise e insights de mercado anti-VEGF
A Degeneração Macular Relacionada com a Idade (DMI) é uma doença ocular que pode agravar-se com o tempo. É a principal causa de perda grave e permanente da visão em pessoas com mais de 60 anos O envelhecimento é um dos fatores de risco para a incidência global de DMRI precoce. A população sénior do mundo está a aumentar a um ritmo rápido. Com o aumento da idade, ocorre um aumento recíproco de doentes idosos devido ao aumento da prevalência de doenças crónicas. O diagnóstico da doença é possível em várias fases, e os testes genéticos e a imagiologia da retina são algumas das técnicas para detetar doenças. O diagnóstico da doença é realizado principalmente por técnicas de imagem óptica e outros processos padrão.
Não existe cura, mas o tratamento para a Degeneração Macular Relacionada com a Idade (DMI) pode atrasar a doença e evitar a perda grave de visão. O tratamento da doença da Degeneração Macular Relacionada com a Idade (DMI) inclui, geralmente, medicamentos e produtos de diagnóstico. Estas técnicas são utilizadas para atingir a parte danificada da retina e permitem a facilidade do tratamento com terapias.
Espera-se que o mercado global de Degeneração Macular Relacionada com a Idade (DMRI) - anti VEGF ganhe crescimento de mercado no período de previsão de 2024 a 2031. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 6,8 % no período de previsão.
O relatório global do mercado da doença de degeneração macular relacionada com a idade (AMD) - anti-VEGF fornece detalhes da quota de mercado, novos desenvolvimentos e análise do pipeline de produtos, o impacto dos participantes do mercado nacionais e localizados, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado, contacte-nos para um resumo do analista. A nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir a meta desejada. A escalabilidade e expansão do negócio das unidades de retalho nos países em desenvolvimento de diversas regiões e a parceria com fornecedores para a distribuição segura de produtos de máquinas e medicamentos são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2024 a 2031 |
|
Ano base |
2023 |
|
Anos históricos |
2022 (personalizável para 2016-2021) |
|
Unidades Quantitativas |
Receita em milhões de dólares |
|
Segmentos cobertos |
Tipo (DMI seca e DMRI húmida), Utilizador final (Hospitais, Clínicas especializadas, Centros de cirurgia ambulatória, Assistência domiciliária e outros), Canal de distribuição (Concurso direto e Venda a retalho) |
|
Países abrangidos |
EUA, Canadá, México, Alemanha, França, Itália Reino Unido, Espanha, Rússia, Áustria, Holanda, Hungria, Polónia, Suíça, Turquia, Noruega, Lituânia, Irlanda, Resto da Europa, Japão, China, Índia, Austrália, Singapura, Sul Coreia, Malásia, Tailândia, Indonésia, Filipinas, Vietname, Resto da Ásia-Pacífico, Brasil, Argentina, Peru, Resto da América do Sul, África do Sul, Egipto, Arábia Saudita, Israel, Emirados Árabes Unidos, Kuwait e Resto do Médio Oriente e África |
|
Participantes do mercado abrangidos |
Regeneron Pharmaceuticals Inc., Biogen, Outlook Therapeutics, Inc., Sulentis, SA, Novartis AG, Genentech, Inc., Bayer AG, Adverum Biotechnologies, Inc., Gensight Biologics, REGENXBIO INC., OCUGEN, INC., MeiraGTX, Limited, Johnson & Johnson Services, Inc., IVERIC bio, Inc., An Astellas Company, KODIAK SCIENCES INC. e Lonis Pharmaceuticals, entre outros. |
Definição de mercado
A terapia anti-VEGF interrompe o crescimento anormal dos vasos sanguíneos na retina, uma característica marcante de doenças como a degeneração macular relacionada com a idade (DMI). Ao inibirem a ação do VEGF, estes fármacos previnem a fuga de vasos e os danos na zona central da visão (mácula). Administrados através de injeções oculares, retardam a perda de visão e, em alguns casos, melhoram a visão. Este tratamento dirigido, fundamental no tratamento da DMRI, restringe a progressão da doença, impedindo o crescimento de vasos sanguíneos problemáticos no olho.
Doença global de degeneração macular relacionada com a idade (DMI) – Dinâmica do mercado anti-VEGF
Esta secção trata da compreensão dos impulsionadores do mercado, das vantagens, das restrições e dos desafios. Tudo isto é discutido em detalhe abaixo:
Motoristas
- Aumento da prevalência de degeneração macular relacionada com a idade
A prevalência de doenças que ameaçam a visão, como o glaucoma , as cataratas e a degeneração macular relacionada com a idade, deverá aumentar nos países desenvolvidos devido ao envelhecimento da população e ao aumento da esperança de vida. Destacam-se como a principal causa de cegueira na população ocidental em idade ativa. Estima-se que quase 60% dos doentes apresentam uma deficiência visual grave que ocorre logo após o nascimento, o que está a impulsionar o crescimento do mercado.
- Aumento da iniciativa estratégica por parte dos principais intervenientes
Associação, o acordo é utilizado pelo player principal para se expandir para uma região diferente do mundo juntamente com a passagem de tecnologia de um player para outro, aumentando a aprovação do produto e a investigação institucional.
São empreendidas pelos players do mercado diversas iniciativas estratégicas, que envolvem a parceria, a aprovação do produto e a colaboração, entre outras. Estas iniciativas ajudam-nos a reforçar a sua presença no mercado e a promover a expansão do mercado. Além disso, algumas iniciativas estratégicas aumentaram a procura pelos seus produtos junto de vários clientes. Espera-se que iniciativas estratégicas como a colaboração, o acordo e a assinatura de acordos de vendas impulsionem o mercado.
Oportunidade
- Aumentando a investigação e o desenvolvimento
A investigação e o desenvolvimento são um pré-requisito para modificar o tratamento para tratar diferentes tipos de doentes. A procura de tratamentos e procedimentos para a Degeneração Macular Relacionada com a Idade (DMI) está a aumentar em todos os países. É por isso que as empresas se concentram continuamente na investigação e desenvolvimento para fornecer com sucesso um tratamento eficaz aos doentes e aos profissionais de saúde.
Os efeitos podem ser observados apenas nos indivíduos de determinadas formas, incluindo fatores potenciadores eficazes, como a evolução da doença, a visão torna-se progressivamente mais comprometida, o tecido da retina degenera e há danos permanentes.
Desafios/ Restrições
- Elevado custo de tratamento e procedimentos
O custo do produto desempenha um fator importante no mercado. Na doença Degeneração Macular Relacionada com a Idade (DMI), observa-se geralmente que são altamente sofisticados, devem ser precisos e outras especificações aumentam o custo do produto. Além disso, o custo associado ao tratamento de longa duração é bastante difícil de suportar por uma pessoa com rendimentos médios. A utilização de serviços de cuidados intensivos e de unidades de cuidados intensivos está a aumentar em todo o mundo e, com o seu custo elevado, é uma grande preocupação no sistema de saúde atual.
Os doentes com perturbação de degeneração são comummente obrigados a um tratamento longo com monetarização frequente e outros usos, levando ao consumo de uma quantidade significativa de recursos de saúde. A maioria dos doentes que não conseguem suportar os custos económicos a longo prazo tem alta nas fases iniciais do tratamento. Mas, isto aumenta as possibilidades e suscetibilidades para novas complicações no diagnóstico, o que exige recursos adicionais de saúde e tratamento, o que está a requalificar o crescimento do mercado.
- Acesso limitado ao tratamento
O tratamento de uma doença depende diretamente da acessibilidade ao serviço disponível para essa doença. A taxa de tratamento de vários tipos de doenças de Degeneração Macular Relacionada com a Idade (DMI) cai devido ao acesso limitado aos hospitais e clínicas especializadas devido aos baixos rendimentos e aos recursos limitados, entre outros.
An interview published in a report in 2019 with the major market players of the drug segment said that they face challenges in providing accessibility to the diagnosis product in the underdeveloped nation. About 285 million individuals worldwide are visually impaired; 80% of these people have curable eye disorders, but limited or no access to adequate care, products, or available technologies improves the prevalence of blindness and decreases the growth of the market.
Recent Developments
- In November 2023, Regeneron Pharmaceuticals, Inc. announced long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg at the American Academy of Ophthalmology (AAO) annual meeting in San Francisco. This is an investor event where the companies try to attract investors, which helps the company increase the R&D
- In August 2023, Astellas Pharma Inc. announced that IZERVAY (avacincaptad pegol intravitreal solution) will be approved by the U.S. Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The rate of GA progression at the 12-month primary endpoint was statistically significantly (p<0.01) lower in two Phase 3 clinical trials with the novel complement C5 inhibitor IZERVAY, making it the only approved treatment for GA
- In November 2022, Sylentis, S.A., announced the recruitment of the first patient in a new phase II dose-finding trial with its compound SYL1801 for treating patients with Neovascular Age-Related Macular Degeneration (AMD). This is a randomized, double-blind, phase II trial with three parallel groups in which different dose levels will be administered to each group of subjects. The study has already started and will recruit 90 patients in different centers in several European countries. The trial's primary objective is to evaluate the effect on visual acuity of SYL1801 at all three doses, administered as one drop daily for six weeks in patients with neovascular AMD
- In May 2022, Adverum Biotechnologies, Inc. announced that the company had presented data at the American Society of Gene and Cell Therapy (ASGCT) 2022 annual meeting on the efficacy and safety outcome of ADVM-022 that supported Phase 2 development plans. This results in evaluating the ADVM-022 dose with new enhanced prophylactic steroid regimens in the subsequent clinical trial
- In March 2022, Novartis AG announced that Beovu (brolucizumab) 6 mg had been authorized by the European Commission (EC) to treat visual impairment caused by Diabetic Macular Edoema (DME). Beovu was initially approved by the EC in 20203 to treat wet age-related macular degeneration; the DME indication marks the medication's second approval. The ruling of the European Community (EC) applies to all 27 EU members and Liechtenstein, Iceland, and Norway
Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market Scope
The global Age-related macular degeneration (AMD) disease - anti VEGF market is categorized into three notable segments on the basis of type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Dry AMD
- Wet AMD
On the basis of type, the market is segmented into dry AMD and wet AMD.
End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Home Healthcare
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.
Distribution Channel
- Retail Sales
- Direct Tender
On the basis of distribution channel, the market is segmented into direct tender and retail sales.
Regional Analysis/Insights: Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market
The global Age-Related Macular Degeneration (AMD) disease - anti VEGF market is categorized into three notable segments on the basis of type, end user, and distribution channel.
The countries covered in this market report U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and Rest of Middle East and Africa.
North America is expected to dominate global Age-Related Macular Degeneration (AMD) disease - anti VEGF due to rising prevalence of age-related macular degeneration. The U.S. is expected to dominate the North America region as it has the largest R&D spending globally and offers trade agreements with several countries, making it the largest market for consumer diagnosis and therapy products. China is expected to dominate the Asia-Pacific region due to the mass production of Age-related macular degeneration (AMD) disease - anti VEGF based products and increasing demand from emerging markets and expansion. Germany is expected to dominate the Europe region as it has the emerging reimbursement policies for the treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Cenário Competitivo e Análise de Participação: Doença Global de Degeneração Macular Relacionada com a Idade (DMI) – Mercado Anti VEGF
O panorama competitivo do mercado global de Degeneração Macular Relacionada com a Idade (DMI) - anti VEGF fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, aprovações de produtos, largura e fôlego do produto, domínio de aplicação, tipo de produto linha de vida curva. Os dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado.
Alguns dos principais players que operam no mercado global de Degeneração macular relacionada com a idade (DMI) - mercado anti-VEGF são a Regeneron Pharmaceuticals Inc., Biogen, Outlook Therapeutics, Inc., Sylentis, SA, Novartis AG, Genentech, Inc., Bayer AG , Adverum Biotechnologies, Inc., Gensight Biologics, REGENXBIO INC., OCUGEN, INC., MeiraGTx Limited, Johnson & Johnson Services, Inc., IVERIC bio, Inc., An Astellas Company, KODIAK SCIENCES INC., e Ionis Pharmaceuticals, entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTERS_
4.3 PRICING ANALYSIS
4.4 STRATEGIC INITIATIVES
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION
6.1.2 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS
6.1.3 INCREASE IN PIPELINE PRODUCTS
6.1.4 INCREASING GERIATRIC POPULATION
6.1.5 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 INCREASING RESEARCH AND DEVELOPMENT
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
6.4 CHALLENGES
6.4.1 LIMITED ACCESS TO TREATMENT
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS
7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE
7.1 OVERVIEW
7.2 WET AMD
7.2.1 MEDICATIONS
7.2.1.1 ANTI-VEGF THERAPY
7.2.1.2 OTHERS
7.2.2 SURGERY
7.3 DRY AMD
8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CLINICS
8.4 AMBULATORY SURGICAL CENTERS
8.5 HOME HEALTHCARE
8.6 OTHERS
9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 RETAIL SALES
9.2.1 HOSPITAL PHARMACIES
9.2.2 RETAIL PHARMACIES
9.2.3 OTHERS
9.3 DIRECT TENDER
10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 U.S.
10.2.2 CANADA
10.2.3 MEXICO
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 U.K.
10.3.4 RUSSIA
10.3.5 ITALY
10.3.6 SPAIN
10.3.7 NETHERLANDS
10.3.8 SWITZERLAND
10.3.9 POLAND
10.3.10 TURKEY
10.3.11 AUSTRIA
10.3.12 HUNGARY
10.3.13 NORWAY
10.3.14 IRELAND
10.3.15 LITHUANIA
10.3.16 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 SINGAPORE
10.4.7 THAILAND
10.4.8 INDONESIA
10.4.9 PHILIPPINES
10.4.10 MALAYSIA
10.4.11 VIETNAM
10.4.12 REST OF ASIA-PACIFIC
10.5 SOUTH AMERICA
10.5.1 BRAZIL
10.5.2 ARGENTINA
10.5.3 PERU
10.5.4 REST OF SOUTH AMERICA
10.6 MIDDLE EAST AND AFRICA
10.6.1 SOUTH AFRICA
10.6.2 SAUDI ARABIA
10.6.3 U.A.E.
10.6.4 ISRAEL
10.6.5 EGYPT
10.6.6 KUWAIT
10.6.7 REST OF SOUTH AFRICA
11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: GLOBAL
12 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 REGENERON PHARMACEUTICALS INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 BAYER AG
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 GENENTECH, INC. (A SUBSIDIARY OF F.HOFFMANN- LA ROCHE LTD)
16.3.1 COMPANY SNAPSHOT
16.3.2 COMPANY SHARE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENT
16.4 NOVARTIS AG
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.4.5.1 AGREEMENT
16.5 IVERIC BIO (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ADVERUM BIOTECHNOLOGIES, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BIOGEN
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 GENSIGHT BIOLOGICS
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 IONIS PHARMACEUTICALS
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 JOHNSON &JOHNSON SERVICES, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 KODIAK SCIENCES INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 MEIRAGTX LIMITED
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
16.13 OCUGEN, INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 OUTLOOK THERAPEUTICS, INC.
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 REGENXBIO INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 SYLENTIS, S.A.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Lista de Tabela
TABLE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 2 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 3 GLOBAL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 GLOBAL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 GLOBAL DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 13 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 GLOBAL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 24 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 25 U.S. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 U.S. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 28 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 29 U.S. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 30 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 31 CANADA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 32 CANADA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 34 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 35 CANADA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 36 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 MEXICO WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 MEXICO MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 39 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 40 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 41 MEXICO RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 43 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 47 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 48 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 49 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 50 GERMANY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 51 GERMANY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 53 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 54 GERMANY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 55 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 FRANCE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 FRANCE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 59 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 60 FRANCE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 61 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 U.K. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 U.K. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 64 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 65 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 66 U.K. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 67 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 RUSSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 RUSSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 71 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 72 RUSSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 73 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 ITALY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 ITALY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 77 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 78 ITALY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 79 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 SPAIN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 SPAIN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 83 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 84 SPAIN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 85 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 NETHERLANDS WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 NETHERLANDS MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 89 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 90 NETHERLANDS RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 91 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 SWITZERLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 SWITZERLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 94 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 95 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 96 SWITZERLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 97 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 POLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 POLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 101 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 102 POLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 103 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 TURKEY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 TURKEY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 107 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 108 TURKEY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 109 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 AUSTRIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 111 AUSTRIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 112 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 113 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 114 AUSTRIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 115 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 HUNGARY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 117 HUNGARY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 118 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 119 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 120 HUNGARY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 121 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 122 NORWAY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 123 NORWAY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 125 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 126 NORWAY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 127 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 IRELAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 IRELAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 131 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 132 IRELAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 LITHUANIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 135 LITHUANIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 136 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 137 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 138 LITHUANIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 139 REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 140 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 141 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 142 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 ASIA-PACIFIC MEDICATION IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 ASIA-PACIFIC WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 145 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 146 ASIA-PACIFIC RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 147 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 CHINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 CHINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 151 CHINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 152 CHINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 JAPAN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 JAPAN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 157 JAPAN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 158 JAPAN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 159 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 INDIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 INDIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 163 INDIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 164 INDIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 165 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 SOUTH KOREA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 SOUTH KOREA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 169 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 170 SOUTH KOREA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 171 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 AUSTRALIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 AUSTRALIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 175 AUSTRALIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 176 AUSTRALIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 177 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 SINGAPORE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 SINGAPORE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 181 SINGAPORE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 182 SINGAPORE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 183 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 THAILAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 THAILAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 187 THAILAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 188 THAILAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 189 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 INDONESIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 INDONESIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 192 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 193 INDONESIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 194 INDONESIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 195 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 PHILIPPINES WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 PHILIPPINES MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 199 PHILIPPINES AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 200 PHILIPPINES RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 201 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 MALAYSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 MALAYSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 205 MALAYSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 206 MALAYSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 207 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 208 VIETNAM WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 VIETNAM MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 210 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 211 VIETNAM AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 212 VIETNAM RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 213 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 214 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 215 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 SOUTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 SOUTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 219 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 220 SOUTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 221 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 BRAZIL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 BRAZIL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 225 BRAZIL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 226 BRAZIL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 227 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 ARGENTINA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 ARGENTINA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 231 ARGENTINA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 232 ARGENTINA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 233 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 234 PERU WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 235 PERU MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 236 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 237 PERU AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 238 PERU RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 239 REST OF SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 240 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 241 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 242 MIDDLE EAST AND AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 243 MIDDLE EAST AND AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 245 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 246 MIDDLE EAST AND AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 247 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 SOUTH AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 SOUTH AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 250 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 251 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 252 SOUTH AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 253 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 SAUDI ARABIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 SAUDI ARABIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 257 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 258 SAUDI ARABIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 259 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 260 U.A.E. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 261 U.A.E. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 263 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 264 U.A.E. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 265 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 ISRAEL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 267 ISRAEL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 268 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 270 ISRAEL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 271 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 272 EGYPT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 EGYPT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 275 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 276 EGYPT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 277 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 KUWAIT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 KUWAIT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 281 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 282 KUWAIT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 283 REST OF SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION)
Lista de Figura
FIGURE 1 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION
FIGURE 2 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: END USER COVERAGE GRID
FIGURE 10 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST RATE IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 13 AN INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE GROWTH OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 WET AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN 2023 AND 2031
FIGURE 15 EUROPE IS THE FASTEST-GROWING MARKET IN GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET
FIGURE 17 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2023
FIGURE 18 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 19 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 20 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, LIFELINE CURVE
FIGURE 21 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2023
FIGURE 22 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 23 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, CAGR (2024-2031)
FIGURE 24 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, LIFELINE CURVE
FIGURE 25 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 26 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 27 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 28 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 29 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SNAPSHOT (2023)
FIGURE 30 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
FIGURE 31 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
FIGURE 32 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
FIGURE 33 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
